News
AI and avatars help to shed light on the secrets of healthy ageing

A new project funded by the EU is aiming to uncover the links between cardiovascular disease (CVD) and mild cognitive impairment (MCI).
Around one third of people living with CVD also have MCI, yet MCI is undiagnosed in an estimated 50-80% of these cases.
The association between the two conditions extends beyond merely sharing well-established risk factors and implies that CVD itself may contribute to MCI, which refers to a stage of cognitive decline greater than normal for a person’s age and education, but not severe enough to impair daily function.
Conversely, dementia is characterised by a progressive decline in cognitive abilities and the ability to live independently.
The overarching ambition of the DORIAN GRAY project is to uncover the mechanisms bridging MCI and CVD, and develop an integrated approach, which aims to promote resilience and improve overall health in the ageing population.
It will start with the analysis of data available in patients with CVD, such as heart failure (HF), in which mechanisms leading to MCI are enhanced, and thereafter the factors aggravating the onset and progression of cognitive impairment in the general population with cardiovascular risk factors (CVRF) will be defined.
Scientific coordinator, Dr Riccardo Proietti of the University of Liverpool, said: “For years, Alzheimer’s Disease (AD) and cerebrovascular dementia were viewed as separate entities. Recent research suggests they may represent a continuum, with overlapping pathways favouring either vascular or parenchymal β-amyloid deposition.
“CVD not only shares risk factors with cognitive impairment (CI) but may also contribute to it, through mechanisms like chronic hypoperfusion, infarcts, and arterial stiffness. However, a unifying theory remains elusive due to the lack of reliable biomarkers for early diagnosis and risk stratification in MCI patients with CVD. The goal of DORIAN GRAY is to develop a neurobiology-based hypothesis linking MCI to CVD, using biomarkers for clinical assessment to inform joint health policies for prevention, while also developing an innovative digital tool that can be used for cognitive enhancement.”
The project will integrate real-world data from multiple sources, including smartwatches, smartphones, tablets, and leverage AI alongside with clinical variables to enable risk stratification and personalised treatment.
This approach can be applied to primary prevention (risk stratification for MCI), secondary prevention (slowing progression toward dementia), and tertiary prevention (reducing the severity of MCI).
This will, in turn, enable the early identification of patterns or ‘fingerprints’ of potential MCI progression, and introduces a paradigm shift in healthcare, applicable to other non-communicable diseases.
A groundbreaking feature of the project is the use of a medical avatar, an innovative technology with vast, yet largely untapped potential in healthcare.
In DORIAN GRAY, avatar-based coaching exergaming (ABCE) — a technology-driven physical activity — will serve as both a cognitive enhancement tool in the exergame component and a lifestyle intervention in the coaching system. Instead of just offering explicit behavioural instructions, ABCE shapes all aspects of a user’s life comprehensively increasing their awareness on physical and mental well-being, positively impacting healthy ageing.
The project will use data from over 300,000 individuals across six countries to develop an AI model for predicting MCI risk and predisposition.
News
Gut-friendly foods may damage heart, charity warns
News
Diabetes patients face increased risk of undiagnosed heart failure

People with diabetes may have undiagnosed heart failure that could be detected by a simple screening blood test, research suggests.
The TARTAN-HF trial found that one in four patients with diabetes who had at least one other risk factor for heart failure had undiagnosed heart failure detected through screening with a blood test and ultrasound scanning of the heart.
Experts said the findings show the extent of unrecognised heart failure in people with diabetes, and how the condition can be detected using a widely available blood test called NT-proBNP, which measures how much strain the heart is under.
They suggest a heart failure screening programme for diabetics could improve diagnosis rates, lead to earlier treatment and potentially reduce the risk of hospitalisation and death.
The study, involving 700 patients, was led by the University of Glasgow in collaboration with AstraZeneca, Roche Diagnostics, Us2.ai, NHS Greater Glasgow and Clyde and NHS Lanarkshire.
Dr Kieran Docherty, clinical senior lecturer at the University of Glasgow’s School of Cardiovascular and Metabolic Health, said: “Our results from the landmark TARTAN-HF trial identified heart failure in a large proportion of people living with diabetes, emphasising the need for a heart failure screening strategy in this group of patients.
“We know that many of the symptoms and signs of heart failure are non-specific, and may go unrecognised as potentially being due to heart failure for a long time.
“The strategy used in our trial is simple and easy to implement in clinical practice, and will aid in the early identification of heart failure in people with diabetes, and facilitate the initiation of medications that we know improve outcomes in patients with heart failure.”
The study, which began more than three years ago, involved more than 700 people with diabetes from the two health board areas who had at least one other risk factor for heart failure.
They were randomly assigned either to receive heart failure screening or to continue with their usual care.
Researchers found screening uncovered a large number of previously unrecognised cases of heart failure. Around one in four, or 24.9 per cent, of those screened were found to have the condition within six months, compared with 1 per cent in the group continuing their usual care.
The study, involving patients with type 1 and type 2 diabetes, found almost all of the participants found to have heart failure had preserved ejection fraction, which can be difficult to detect without dedicated testing.
The findings of the TARTAN-HF trial were presented at the American College of Cardiology conference taking place from 28 to 30 March in New Orleans in the US.
Dr Edward Piper, medical director at AstraZeneca UK, said: “Delayed diagnosis and treatment of heart failure in people with type 2 diabetes contributes to poor long-term outcomes. TARTAN-HF demonstrates that targeted, risk-based screening can identify previously undiagnosed heart failure in approximately one in four high-risk patients with diabetes, enabling earlier intervention with guideline-directed therapy.”
Dr Christian Simon, head of global medical affairs at Roche Diagnostics, said: “We are proud to have supported the landmark TARTAN-HF trial. These findings demonstrate the transformative power of early, accessible diagnostics like the NT-proBNP blood test.
“By identifying unrecognised heart failure in people with diabetes, we enable clinicians to initiate appropriate treatments sooner, ultimately improving patient outcomes and lives.”
News
UK government announces £6.3m fund to boost men’s health

The UK has launched a £6.3m men’s health fund to back local projects aimed at helping men and boys live longer, healthier lives.
The Men’s Health Community Fund is a partnership between the Department of Health and Social Care, Movember and People’s Health Trust.
The government is contributing £3m, while the two charities are more than doubling that to take the total to £6.3m.
Grants will support community projects reaching underserved men and boys aged 16 and over, particularly in the most disadvantaged areas and at key points in their lives such as becoming a father, losing a job or retiring.
Projects could include support for new fathers, activities for men facing loneliness and social isolation, services to help young men engage with the health system, and support for men in work, out of work and moving into retirement.
The programme will bring together voluntary, community and social enterprise organisations to test new ways of reaching men who are least likely to use traditional health services.
An evaluation funded through the National Institute for Health and Care Research will assess what works and help inform future policy and delivery.
Health and social care secretary Wes Streeting said: “Too many men across the country are living shorter, less healthy lives, particularly those in our most disadvantaged communities.
“This new partnership will help men get the support they need in the places they feel most comfortable, their communities, among people they trust.
“By working with expert charities and local organisations, we can reach the men who are too often missed by traditional services and help them take better care of their mental and physical health.”
“It is a key step in delivering our first ever Men’s Health Strategy and driving forward our ambition to halve the gap in healthy life expectancy between the richest and poorest areas.”
The Men’s Health Strategy sets out plans to tackle the physical and mental health challenges men and boys face.
Men can be less likely to seek help and more likely to suffer in silence, while higher rates of smoking, drinking, gambling and drug use are damaging men’s health and affecting families, workplaces and communities.
The government is also investing £3.6m over the next three years in suicide prevention projects for middle-aged men in local communities across areas of England where men are most at risk, many of which are also among the most deprived. Suicide is one of the biggest killers of men under 50, and three-quarters of all suicides are men.
The projects will aim to break down barriers middle-aged men face in seeking support, including stigma around asking for help and a lack of awareness of what is available and how to access it.
They will be co-designed with experts and men with lived experience of mental health crises and suicidal thoughts.








